A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Q-122 for the Treatment of Vasomotor Symptoms in Female Breast Cancer Patients/Survivors Taking Tamoxifen or an Aromatase Inhibitor

This is a Phase 2 proof-of-concept (POC) study designed to determine the effectiveness of Q-122 for the treatment of Vasomotor Symptoms (VMS) versus placebo. Participants who meet all eligibility criteria following the Screening/Run-In period will be randomized to 1 of 2 treatment arms; blinded Q-122 or placebo for a period of 28 days. All participants will be followed for a 2-week, drug-free, follow-up period after their last dose of blinded Q-122/placebo before termination from the study.

开始日期2018-10-24

申办/合作机构

QUE Oncology Inc

[+1]

ACTRN12617001542381 / CompletedN/A

A randomized, open-label study evaluating the effects of food and dosing regimen on Q-122 pharmacokinetics in healthy female volunteers

开始日期2017-11-30

申办/合作机构

QUE Oncology Inc

NCT04080297 / Completed临床1期

A Two Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Effect on Vasomotor Symptoms of Q-122 in Female Subjects With Breast Cancer and Receiving an Aromatase Inhibitor or Tamoxifen

Open-label, two dose study of Q-122, over a 4 week treatment period to explore the effects of Q-122 in a population of women with a history of breast cancer taking an aromatase inhibitor or tamoxifen.

开始日期2014-01-10

申办/合作机构

QUE Oncology Inc

100 项与 MSX-122 相关的临床结果

登录后查看更多信息

100 项与 MSX-122 相关的转化医学

登录后查看更多信息

100 项与 MSX-122 相关的专利（医药）

登录后查看更多信息

项与 MSX-122 相关的文献（医药）

2023-05-05·The Journal of organic chemistry

N-Alkylation of Amines by C1-C10 Aliphatic Alcohols Using A Well-Defined Ru(II)-Catalyst. A Metal-Ligand Cooperative Approach.

Article

作者: Chakraborty, Santana ; Pal, Subhasree ; Paul, Nanda D. ; Chakraborty, Subhajit ; Guin, Amit Kumar

A Ru(II)-catalyzed efficient and selective N-alkylation of amines by C1-C10 aliphatic alcohols is reported. The catalyst [Ru(L^1a)(PPh₃)Cl₂] (1a) bearing a tridentate redox-active azo-aromatic pincer, 2-((4-chlorophenyl)diazenyl)-1,10-phenanthroline (L^1a) is air-stable, easy to prepare, and showed wide functional group tolerance requiring only 1.0 mol % (for N-methylation and N-ethylation) and 0.1 mol % of catalyst loading for N-alkylation with C3-C10 alcohols. A wide array of N-methylated, N-ethylated, and N-alkylated amines were prepared in moderate to good yields via direct coupling of amines and alcohols. 1a efficiently catalyzes the N-alkylation of diamines selectively. It is even suitable for synthesizing N-alkylated diamines using (aliphatic) diols producing the tumor-active drug molecule MSX-122 in moderate yield. 1a showed excellent chemo-selectivity during the N-alkylation using oleyl alcohol and monoterpenoid β-citronellol. Control experiments and mechanistic investigations revealed that the 1a-catalyzed N-alkylation reactions proceed via a borrowing hydrogen transfer pathway where the hydrogen removed from the alcohol during the dehydrogenation step is stored in the ligand backbone of 1a, which in the subsequent steps transferred to the in situ formed imine intermediate to produce the N-alkylated amines.

2022-11-01·Lancet (London, England)1区 · 医学

Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial

1区 · 医学

Article

作者: Latifi, Ardian ; Davis, Susan R ; Baber, Rodney J ; Stuckey, Bronwyn G A ; Hickey, Martha ; Walker, Michael G ; Stearns, Vered ; Vrselja, Amanda

BACKGROUND:

Vasomotor symptoms (hot flushes and night sweats) are experienced by more than two-thirds of women with breast cancer taking oral adjuvant endocrine therapy. Safe and effective treatments are lacking. Q-122 is a novel, non-hormonal compound that has shown promise for reducing vasomotor symptoms by modulation of oestrogen-responsive neurons in the hypothalamus. We aimed to assess the efficacy and safety of Q-122 in women with breast cancer taking oral adjuvant endocrine therapy and experiencing vasomotor symptoms.

METHODS:

We conducted a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial at 18 sites in Australia, New Zealand, and the USA. Eligible participants were women, aged 18-70 years, taking a stable dose of tamoxifen or an aromatase inhibitor following breast cancer and experiencing at least 50 self-reported moderate to severe vasomotor symptoms per week. Participants were randomly assigned (1:1) using an interactive web response system to oral Q-122 100 mg or identical placebo, twice daily for 28 days. Randomisation was stratified by BMI (≤30 kg/m² or >30 kg/m²) and use of any of a selective serotonin reuptake inhibitor, selective norepinephrine reuptake inhibitor, gabapentin, or pregabalin. Q-122 and placebo capsules were identical in appearance and containers identically labelled. During the double-blind treatment and analysis phases, the participants, investigators, clinical research organisation staff, and sponsor were masked to treatment allocation. The primary outcome was the difference in the mean percentage change from baseline in the Vasomotor Symptom Severity Score of moderate and severe hot flushes and night sweats (msVMS-SS) between Q-122 and placebo after 28 days of treatment. Primary analysis was by modified intention-to-treat and safety was assessed in all participants receiving at least one dose of study drug. This study is registered at ClinicalTrials.gov, NCT03518138.

FINDINGS:

Between Oct 24, 2018, and Sept 9, 2020, 243 patients were screened, 131 of whom were randomly assigned and received treatment (Q-122 n=65 and placebo n=66). Q-122 resulted in a significantly greater mean percentage change in msVMS-SS from baseline over 28 days of treatment compared with placebo (least squares mean: Q-122 -39% [95% CI -46 to -31] vs placebo -26% [-33 to -18]; p=0·018). Treatment-emergent adverse events were generally mild to moderate and similar between the two groups (treatment-related treatment-emergent adverse events in 11 [17%] of 65 patients in the Q-122 group vs nine [14%] of 66 in the placebo group); zero patients in the Q-122 group and two (3%) patients in the placebo group had serious adverse events.

INTERPRETATION:

Q-122 is an effective and well tolerated non-hormonal oral treatment for vasomotor symptoms in women taking oral adjuvant endocrine therapy after breast cancer. Our results support the conduct of larger and longer studies of Q-122, with potential use extending to postmenopausal women who require an alternative to menopausal hormone therapy.

FUNDING:

QUE Oncology.

2022-07-01·International immunopharmacology

MSX-122: Is an effective small molecule CXCR4 antagonist in cancer therapy?

Review

作者: Ghasemi, Kosar ; Ghasemi, Kimia

Chemokines, a subgroup of cytokines along with their receptors, are involved in various biologic processes and regulation of a wide range of immune responses in different physiologic and pathologic states such as tissue repair, infection, and inflammation. C-X-C motif chemokine receptor 4 (CXCR4), a G-protein-coupled receptor (GPCR), has one identified natural ligand termed stromal-derived factor-1(SDF-1 or CXCL12). Evidence demonstrated that the ligation of SDF-1 to CXCR4 initiates several intracellular signaling pathways, regulating cell proliferation, survival, chemotaxis, migration, angiogenesis, adhesion, as well as bone marrow (BM)-resident cells homing and mobilization. Additionally, CXCR4 is expressed by tumor cells in blood malignancies and solid tumors. Therefore, CXCR4 is considered a potential therapeutic target in cancer therapy, and CXCR4 antagonists, including AMD3100, MSX-122, BPRCX807, WZ811, Motixafortide, TN14003, AMD3465, and AMD1170, have been employed in experimental and clinical studies to enhance cancer therapy. MSX-122 is a specific small-molecule antagonist of CXCR4/CXCL12 and the only orally available non-peptide CXCR4 antagonist with promising anti-cancer properties. Studies have shown that MSX-122 is particularly important in treating metastatic cancers and has great therapeutic potential. Accordingly, this review summarized the characteristics of MSX-122 and its effects on the CXCL12/CXCR4 axis as well as cancer therapy.

项与 MSX-122 相关的新闻（医药）

2023-09-12

·PRNewswire

Menopause Market to Grow Rapidly at a CAGR of 1.2% by 2032, Predicts DelveInsight

The menopause market is anticipated to surge significantly in the coming years due to the emergence of new products in the pipeline. In addition, persistently rising cases of menopause in the forecast period will help increase the menopause treatment market. LAS VEGAS, Sept. 12, 2023 /PRNewswire/ -- DelveInsight's Menopause Market Insights report includes a comprehensive understanding of current treatment practices, menopause emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan]. Key Takeaways from the Menopause Market Report As per DelveInsight analysis, the menopause market size in the 7MM was approximately USD 11 billion in 2022. According to the assessment done by DelveInsight, the total number of women in menopause in the 7MM comprised approximately 100 million cases in 2022 and are projected to increase during the forecast period. Leading menopause companies such as Viramal Limited, Simbec Research, Estetra, Mithra Pharmaceuticals, Bayer, Nerre Therapeutics Ltd., Mitsubishi Tanabe Pharma America Inc., MenoGeniX, QUE Oncology, Fervent Pharmaceuticals, and others are developing novel menopause drugs that can be available in the menopause market in the coming years. The promising menopause therapies in the pipeline include Transdermal Estradiol Cream (VML-0203), DONESTA (E4, Estetrol), Elinzanetant (BAY3427080), MT-8554 (Elismetrep), MNGX-100 (Filgrastim/G-CSF), Q-122 (MSX-122), FP-101, and others. Discover which therapies are expected to grab the major menopause market share @ Menopause Market Report Menopause Overview Menopause is a natural biological process that marks the end of a woman's reproductive years. It usually occurs between the ages of 45 and 55, with an average age of around 51. This phase is characterized by a decline in the production of hormones like estrogen and progesterone, leading to the cessation of menstruation and fertility. The primary cause of menopause is the aging of the ovaries, which results in a reduced number of eggs and a decline in hormone production. However, certain medical procedures like hysterectomy, chemotherapy, and radiation therapy can induce menopause prematurely. Menopause brings about a range of symptoms that can vary widely from woman to woman. Common menopause symptoms include hot flashes, night sweats, mood swings, irritability, fatigue, vaginal dryness, and sleep disturbances. These symptoms occur due to the hormonal fluctuations that take place during the transition to menopause. Diagnosing menopause is often based on a woman's age, medical history, and symptoms. A key factor is the absence of menstruation for 12 consecutive months, signaling the end of the reproductive period. In some cases, healthcare providers may recommend blood tests to measure hormone levels, such as follicle-stimulating hormone (FSH) and estrogen, to confirm the onset of menopause. Menopause Epidemiology Segmentation DelveInsight estimates that there were approximately 100 million total women in menopause in the 7MM in 2022. For the age-specific analysis, the number of cases of menopause were distributed across various age groups, such as <40 years, 40–50 years, 51–60 years, and 61–65 years, in the 7MM. As per the analysis, the highest number of cases were estimated in the age-group 51-60 years and the lowest in <40 years with 64 million and 3.4 million cases, respectively in 2022. The menopause market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Total Number of Women in Menopause Stage-Specific Distribution of Women in Menopause Age-Specific Distribution of Women in Menopause Number of Women in Menopause with Vasomotor Symptoms Number of Women in Menopause with Moderate-to-Severe Vasomotor Symptoms Menopause Treatment Market The North American Menopause Society (NAMS) suggests waiting until the hot flashes become troublesome to the woman before seeking treatment. The intensity of symptoms, an assessment of treatment-related risks, and the woman's views towards menopause and drugs should all be considered before starting treatment. Duavee (bazedoxifene acetate/conjugated estrogens) is the first and only medicine that combines CE with an estrogen agonist/antagonist, commonly known as a selective estrogen receptor modulator (SERM), for the treatment of menopausal VMS. Duavee employs bazedoxifene rather than progestin to help protect the uterine lining from hyperplasia that may occur as a result of estrogen-only treatment. Many women use non-prescription therapies to address disorders such as hot flashes, such as isoflavones, black cohosh, and progesterone-containing hormone lotions. The clinical evidence for the efficacy and long-term safety of these therapies is insufficient. Furthermore, most over-the-counter medications for hot flashes are classified as nutritional supplements and, as such, are not regulated by the US Food and Drug Administration. Prescription medications for various purposes that have demonstrated some benefit in alleviating hot flashes are available for women who have hot flashes but cannot undergo hormone therapy. Certain prescription antidepressants may reduce hot flashes in women, including those with a history of breast cancer. Others include gabapentin, clonidine, and methyldopa. The NAMS recommends that women who need relief from mild menopause-related hot flashes first consider lifestyle changes such as manipulating the environment to keep the core body temperature cool, getting regular exercise, quitting smoking, and using relaxation techniques such as paced respiration. To know more about menopause treatment, visit @ Menopause Treatment Drugs Key Menopause Therapies and Companies Transdermal Estradiol Cream (VML-0203): Viramal Limited/Simbec Research DONESTA (E4, Estetrol): Estetra/Mithra Pharmaceuticals Elinzanetant (BAY3427080): Bayer|Nerre Therapeutics Ltd. MT-8554 (Elismetrep): Mitsubishi Tanabe Pharma America Inc. MNGX-100 (Filgrastim/G-CSF): MenoGeniX Q-122 (MSX-122): QUE Oncology FP-101: Fervent Pharmaceuticals Learn more about the FDA-approved drugs for menopause @ Drugs for Menopause Treatment Menopause Market Dynamics The menopause market dynamics are undergoing significant shifts as societal awareness of women's health and well-being continues to grow. With an aging population and increasing focus on women's empowerment, there's a heightened demand for innovative products and services addressing the physical and emotional challenges associated with menopause. This has spurred a surge in research and development, leading to the creation of a diverse range of hormone replacement therapies, herbal supplements, lifestyle apps, and personalized health plans. As more women seek effective and holistic solutions, companies are embracing a more consumer-centric approach, tailoring their offerings to individual needs and preferences. Additionally, discussions around menopause are becoming less taboo, allowing for open dialogue and information-sharing, further shaping the menopause market dynamics by fostering a supportive ecosystem for women navigating this life stage. However, despite the potential for growth, this menopause market is not without its barriers. Stringent regulatory processes for hormonal treatments and supplements, coupled with concerns about product safety and efficacy, pose challenges for menopause market entrants. Additionally, cultural stigmas and misinformation surrounding menopause still exist in certain societies, inhibiting open discussions and the adoption of new solutions. Economic disparities and limited access to healthcare further compound these issues, preventing equal menopause market penetration. Overcoming these barriers requires a multi-faceted approach, involving education, regulatory reforms, and inclusive product development, to truly tap into the menopause market's potential. Scope of the Menopause Market Report Therapeutic Assessment: Menopause current marketed and emerging therapies Menopause Market Dynamics: Attribute Analysis of Emerging Menopause Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's Views, Analyst's Views, Menopause Market Access and Reimbursement Discover more about menopause drugs in development @ Menopause Clinical Trials Table of Contents Related Reports Hot Flashes Pipeline Hot Flashes Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key hot flashes companies, including Veru Healthcare, Fervent Pharmaceuticals, Ogeda, Bayer, Lundbeck A/S, TherapeuticsMD, MenoGeniX, Mitsubishi Tanabe Pharma, QUE Oncology, Pherin Pharmaceuticals, among others. Hot Flashes Market Hot Flashes Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key hot flashes companies, including Veru Healthcare, Fervent Pharmaceuticals, Ogeda, Bayer, Lundbeck A/S, TherapeuticsMD, MenoGeniX, Mitsubishi Tanabe Pharma, QUE Oncology, among others. Menopause Global Market Menopause Market Insights, Competitive Landscape, and Market Forecast – 2028 report deliver an in-depth understanding of the disease, market trends, market drivers, market barriers, and key menopause companies including ISIDEN, Novapharm, Arkopharma, Pileje, Thermamex, ÉLERTÉ Laboratories, Serelys Pharma, Besins Healthcare, Bayer, ITALFARMACO S.p.A, Pfizer Inc, Mylan NV, Teva Pharmaceuticals, TherapeuticsMD, Inc, Novo Nordisk, Novartis, Millicent Pharma, PADAGIS LLC, Vertical Pharmaceuticals LLC, Amgen, among others. Vasomotor Symptoms of Menopause Pipeline Vasomotor Symptoms of Menopause Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key vasomotor symptoms of menopause companies, including Mithra Pharmaceuticals, Acer Therapeutics, QUE Oncology, Bayer, Endoceutics, Astellas Pharma, Mitsubishi Tanabe Pharma, MenoGenix, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

2022-11-10

·PRNewswire

QUE Oncology's non-hormonal therapy reduces hot flushes and night sweats in women with breast cancer, published in The Lancet

MELBOURNE, Australia, Nov. 10, 2022 /PRNewswire/ -- QUE Oncology announces the results of its Phase II trial of Q-122, a novel non-hormonal oral therapy for the treatment of vasomotor symptoms (commonly known as hot flashes/flushes and night sweats) in women taking endocrine therapy for breast cancer, have been published in The Lancet. More than 75 per cent of breast cancers are hormone-sensitive, with endocrine therapy being the standard treatment option[1]. Endocrine therapy is recommended for 5-10 years after cancer treatment for those women that had hormone-sensitive breast cancer, to prevent disease recurrence. However, approximately 70 per cent of women taking endocrine therapy have vasomotor symptoms that contribute to over one third of women prematurely stopping this important therapy. The Phase II study was a multicentre, randomised, double-blind, placebo-control trial involving 131 women taking endocrine therapy (tamoxifen or an aromatase inhibitor) following breast cancer. Q-122 therapy significantly reduced the frequency and severity of moderate and severe vasomotor symptoms, with associated improvement in quality of life, compared with placebo. Q-122 was well tolerated with no serious adverse effects. These results demonstrate the promise of Q-122 as a novel and differentiated, non-hormonal treatment of vasomotor symptoms for women with breast cancer taking endocrine therapy, and the potential for its use in post-menopausal women experiencing similar symptoms. "Our research findings published in The Lancet demonstrate efficacy of Q-122 as a non-hormonal oral treatment for vasomotor symptoms in women taking oral adjuvant endocrine therapy after breast cancer, with no evidence of treatment side effects," explains Principal Investigator and Senior Author, Professor Susan Davis Director, of the Monash University Women's Health Research Program. "In addition to a reduction in flushes and sweats, women who received Q-122 in the study reported a significantly lower likelihood of their hot flushes and sweats interfering with their sleep, and social and leisure activities, compared with placebo. If Q-122 can provide relief from these symptoms, it holds great potential for reducing discontinuation of endocrine therapy, enabling ongoing protection against breast cancer recurrence. This is an extremely important potential benefit of Q-122 beyond symptom relief alone," Professor Davis added. QUE Oncology was formed through a joint venture between Emory University in Atlanta and the University of Queensland (UQ) research commercialisation company, UniQuest. The company has been supported by leading life science investors, including the Brandon Capital-managed Brandon BioCatalyst and Uniseed. "It's great to see extremely positive results from QUE Oncology's Phase II trials published in the world's leading independent general medical journal. The research highlights the need for a therapy for patients undergoing endocrine therapy for breast cancer who are experiencing vasomotor symptoms, but also the broader potential for Q-122 beyond this patient group, including postmenopausal women, of which 70-80 per cent experience vasomotor symptoms," says Dr Chris Nave, Chairman of QUE Oncology and CEO of Brandon BioCatalyst. The results of QUE Oncology's Phase II study support the conduct of larger and longer studies of Q-122, with potential use extending to postmenopausal women who require an alternative to oestrogen therapy for vasomotor symptoms. [1] Bell RJ, Fradkin P, Schwarz M, Davis SR. Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptor positive invasive breast cancer nearly 4 years from diagnosis. Menopause. 2013 Jan;20(1):15-21 ENDS Q-122 Phase 2 study: Eligible participants were women, aged 18–70 years, taking a stable dose of tamoxifen or an aromatase inhibitor following breast cancer and experiencing at least 50 self-reported moderate to severe vasomotor symptoms per week. Participants were randomly assigned (1:1) using an interactive web response system to oral Q-122 100 mg or identical placebo, twice daily for 28 days. Randomisation was stratified by BMI (≤30 kg/m² or >30 kg/m²) and use of any of a selective serotonin reuptake inhibitor, selective norepinephrine reuptake inhibitor, gabapentin, or pregabalin. Between Oct 24, 2018, and Sept 9, 2020, 243 patients were screened, 131 of whom were randomly assigned and received treatment (Q-122 n=65 and placebo n=66). Q-122 resulted in a significantly greater mean percentage change in msVMS-SS from baseline over 28 days of treatment compared with placebo (least squares mean: Q-122, –39% [95% CI –46 to –31] vs placebo –26% [–33 to –18]; p=0・018). Treatment-emergent adverse events were generally mild to moderate and similar between the two groups (treatment-related treatment-emergent adverse events in 11 [17%] of 65 patients in the Q-122 group vs nine [14%] of 66 in the placebo group); zero patients in the Q-122 group and two (3%) patients in the placebo group had serious adverse events. About QUE Oncology QUE Oncology is a clinical stage company developing drugs for unmet medical needs. The lead program, Q-122 is in development as a novel non-hormonal treatment for moderate to severe vasomotor symptoms (hot flashes and night sweats) in postmenopausal women, and in cancer patients receiving hormone therapy. The clinical results of Q-122, as an effective and well tolerated non-hormonal oral treatment for vasomotor symptoms, warrant its further development in larger and longer studies. QUE Oncology was formed through a joint venture between Emory University in Atlanta and the University of Queensland research commercialization company, UniQuest. QUE Oncology is backed by venture capital groups, led by Brandon Capital-managed Brandon BioCatalyst and Uniseed. About Q-122 Q-122 is an orally bioavailable, non-hormonal, small molecule that is being developed as a treatment for vasomotor symptoms in postmenopausal women, and in cancer patients receiving hormone therapy. Promising clinical activity and an excellent safety profile of Q-122 has been demonstrated in early clinical trials of healthy volunteers, cancer patients, and breast cancer survivors taking endocrine therapy who were experiencing vasomotor symptoms (over 125 total subjects). Functionally in preclinical studies, Q-122 exhibits a novel mechanism of action, which is not an NK3 receptor antagonist. SOURCE QUE Oncology

小分子药物

2022-05-26

·新浪医药新闻

境况逆转？默沙东molnupiravir在美销售陷低迷辉瑞Paxlovid大幅激增

编译丨范东东编辑丨小宝 01全美辉瑞Paxlovid使用量激增从4月中旬开始，美国COVID-19的感染率呈现上升趋势，但死亡率一直保持相对稳定，随着感染患者数量的上升，辉瑞Paxlovid使用量激增。美国一位卫生官员曾表示，在4月10日至5月14日的四周时间里，全美Paxlovid使用增加了315%以上。而根据美国健康与社会服务部（HHS）提供的数据显示，在最新过去的一周，Paxlovid使用量已经超过16.2万个疗程。值得一提的是，此前，辉瑞Paxlovid曾因2022年Q1Paxlovid业绩不如预期，引发市场质疑。但在Q122财报指引中，辉瑞对于Paxlovid2022年的220亿美元的预计销售额不变，只是指出外汇方面有大约5亿美元的不利影响。如今Paxlovid销量开始激增，2022年的销量是否能按预计完成呢？ 02Paxlovid使用量激增原因及耐药性加剧引担忧对于Paxlovid的使用量激增原因，美国HHS高级官员归因于拜登政府松绑治疗限制的措施，该政策允许快筛阳性的患者直接使用Paxlovid进行治疗。而美国民众目前对于接受Paxlovid治疗后，很可能还会再次发生新冠感染表示非常担忧。此前，美国疾病控制与预防中心（CDC）在一份声明证实，数十名COVID-19患者在完成Paxlovid治疗后出现了再次感染新冠肺炎的情况。对此，美国CDC建议患者在症状再次出现时，延长隔离期并注意防护。比如在症状改善和体温正常的情况下，延长隔离期至十天。而辉瑞CEO艾伯乐曾公开表示，对于吃完一个疗程Paxlovid后新冠症状复发的患者，应该继续服用另外的疗程，不过FDA很快驳斥了这个建议。 03默沙东molnupiravir销量陷低迷，AZ的Evusheld销量不佳但使用率较高据悉，目前除Paxlovid之外，美国市场上其他新冠治疗方案使用量欠佳。默沙东新冠药物molnupiravir（Lagevrio）近日就一直很难摆脱销售量低迷的困境，一直在努力摆脱库存，据悉，过去一周美国市场仅使用了约2.0万疗程molnupiravir。值得一提的是，默沙东2022年Q1财报中显示，Molnupiravir的销售额已经达到32亿美元，对比此前预计2022年整年的销售额为50-60亿美元，整体大超预期。此外，阿斯利康（AstraZeneca）新冠药物——单克隆抗体Evusheld的销量虽不尽如人意但使用率还算较高。据悉，Evusheld过去一周只使用了大约1.6万个疗程。 04美国各州新冠药物的订购量以及使用量根据最新的HHS数据，从预定量、使用率来看，目前美国各州—— 1）Paxlovid预定量约为244万疗程，使用率超34%。 2）molnupiravir预定量约为188万疗程，使用率约13%。 3）Evusheld预定量约为70万疗程，使用率超38%。值得注意的是，美国HHS针对Covid-19疗法的分布数据和相关信息正在变得越来越不透明。此前，拜登政府要求美国HHS和美国各州之间每周发布关于Covid-19治疗物资分配的通话录音，但这些电话均被要求保密，之前的录音也已从公开网站上删除。此外，因为美国HHS会不定时删除前一周的公开数据，因此美国每周的治疗给药数量也需要重新独立计算。参考来源： 1、Concerns Mount Over COVID-19 'Rebounds' After Treatment With Pfizer's Paxlovid 2、US sees spike in Paxlovid usage as Merck's molnupiravir and AstraZeneca's Evusheld are slower off the shelf

财报

100 项与 MSX-122 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB12715

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
乳腺癌	临床2期	美国	QUE Oncology Inc	2018-10-24
乳腺癌	临床2期	澳大利亚	QUE Oncology Inc	2018-10-24
乳腺癌	临床2期	新西兰	QUE Oncology Inc	2018-10-24
潮热	临床2期	美国	QUE Oncology, Inc.	2018-10-24
潮热	临床2期	澳大利亚	QUE Oncology, Inc.	2018-10-24
潮热	临床2期	新西兰	QUE Oncology, Inc.	2018-10-24
血管舒缩症	临床2期	澳大利亚	QUE Oncology, Inc.	2018-09-30
血管疾病	临床2期	-	Altiris Therapeutics, Inc.	-
局部晚期恶性实体瘤	临床1期	美国	Metastatix, Inc.	2007-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03518138 (Pubmed \| Lancet) 人工标引	临床2期	血管舒缩症 \| 乳腺癌	131	Q-122	簾鹹糧鏇齋窪壓鬱餘鏇(齋糧夢壓糧憲繭鏇繭膚) = 憲廠糧簾蓋蓋衊淵衊獵遞鏇鏇憲艱餘簾繭鏇鬱 (獵醖製鹽網膚蓋醖膚顧, -46 ~ -31) 更多	积极	2022-11-12
				Placebo	簾鹹糧鏇齋窪壓鬱餘鏇(齋糧夢壓糧憲繭鏇繭膚) = 衊鬱廠鬱簾選鹹糧憲廠遞鏇鏇憲艱餘簾繭鏇鬱 (獵醖製鹽網膚蓋醖膚顧, -33 ~ -18) 更多
NCT04080297 (CTgov)	临床1期	血管舒缩症 \| 乳腺癌	21	oral capsule of Q-122 (100 mg Q-122)	鬱積廠築醖鑰構範夢獵(鑰壓觸窪鬱築膚選鹹夢) = 廠蓋築積夢憲憲膚壓廠鹽廠顧淵膚鏇觸醖淵膚 (憲艱獵鬱構窪蓋齋齋遞, 糧夢願繭鹹餘願餘築鏇 ~ 鏇鏇廠窪膚觸糧網壓廠) 更多	-	2020-02-28
				oral capsule of Q-122 (200 mg Q-122)	鬱積廠築醖鑰構範夢獵(鑰壓觸窪鬱築膚選鹹夢) = 鹽觸膚窪繭壓淵鑰衊鏇鹽廠顧淵膚鏇觸醖淵膚 (憲艱獵鬱構窪蓋齋齋遞, 網簾憲構願選衊範積襯 ~ 憲醖鏇艱築鏇顧醖醖壓) 更多